CD19 and lymphoma: Using CD19 as target has several advantages; first, CD19 is a B lineage-associated antigen expressed by most B cell leukemia and lymphoma, second, hematologic malignancies are more easily accessible than solid cancer cells, and third, CD19 CAR T cell-induced aplasia of healthy B cells can be clinically managed.